Anteris Technologies Global Corp.
AVRHealthcareNASDAQMedical Devices · Last scanned Oct 24, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Anteris Technologies Global Corp. focuses on Medical Devices services and products. Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. The $571.4M market capitalization puts AVR squarely in small-cap range for its industry. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve.
Market Cap
$571.4M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-5.09
EPS (TTM)
$-1.95
EPS (Fwd)
$-1.15
ROE
-74.7%
ROA
-42.5%
Cash
$256.9M
Total Debt
$3.3M
Free CF
-$51.1M
52W Change
17.4%
Annual Financials
Cash vs Debt
Where AVR stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, AVR finished 21.17% below its 150-day moving average ($7.84) and 15.69% below its 200-day moving average ($7.33). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is AVR overbought or oversold?
At the October 20, 2026 close, AVR's RSI(14) was 24.0, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $256.9M in cash and $3.3M in debt, AVR maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$51.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -74.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $3.1M (2022) to $1.9M (2025), a 39% decline worth watching.
With cash comfortably exceeding debt, AVR has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing AVR.